
Browsing restrictions can be lifted for a fee.
Allied Biotech Corporation manufactures and sells carotenoids worldwide. Its products include Beta-Carotene that offers yellow to reddish orange shades to appeal color in various applications; Beta-Apo-8'-Carotenal, which is used as a food colorant, and provides a range of orange to red shades; and Lycopene, which offers a range of red shades as a nutrient for food, dietary supplements, and pharmaceutical products. The company also provides Canthaxanthin, which offers a range of shades of reddish orange for food and beverage applications; Lutein, a carotenoid that provides a range of green leafed vegetables, such as spinach, kale, broccoli, and egg yolks.; and Nano Coenzyme Q10, an antioxidant, which is used in the transformation of energy in the body. It serves food, beverage, dietary supplement, and feed industries. Allied Biotech Corporation was founded in 2001 and is headquartered in Taipei, Taiwan.
1780
立弘
2.81%
(0.03)
The most recent financial report for 立弘 (1780) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1780's short-term business performance and financial health. For the latest updates on 1780's earnings releases, visit this page regularly.
According to historical valuation range analysis, 立弘 (1780)'s current price-to-earnings (P/E) ratio is 13.55, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 立弘 (1780) reported an Operating Profit of 20.99M with an Operating Margin of 9.81% this period, representing a decline of 48.51% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 立弘 (1780) announced revenue of 213.92M, with a Year-Over-Year growth rate of -43.56%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 立弘 (1780) held Total Cash and Cash Equivalents of 789.08M, accounting for 0.38 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 立弘 (1780) achieved the “three margins increasing” benchmark, with a gross margin of 37.32%%, operating margin of 9.81%%, and net margin of 22.75%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1780's profit trajectory and future growth potential.
According to the past four quarterly reports, 立弘 (1780)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.51. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
立弘 (1780)'s Free Cash Flow (FCF) for the period is -18.06M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 233.83% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.